• CARMIL Membrane Binding and Actin Assembly

  2026-08-21

  Mooren and colleagues show that the CARMIL membrane-binding domain is an active regulator rather than a passive localization element: it recruits the CARMIL capping-protein-binding region to membrane surfaces, promotes capping protein activation, and supports Arp2/3-dependent actin assembly. The study also identifies CP-dependent release of the membrane-binding domain, providing a mechanistic explanation for how activated capping protein can transition from membrane recruitment to soluble barbed-end regulation.

• ZCL278 and the Translational Logic of Cdc42

  2026-08-20

  A thought-leadership analysis of ZCL278 as a selective Cdc42 inhibitor, connecting its mechanistic effects on motility and neuronal morphology with emerging evidence that Cdc42 regulates kidney fibrosis. The article provides practical validation strategies, translational decision gates, and a cautious roadmap for disease-focused research.

• CP-673451: Selective PDGFRα/β Inhibitor Workflows

  2026-08-20

  CP-673451 supports mechanism-focused studies of PDGFR signaling, PDGF-BB-driven angiogenesis, and tumor growth in xenograft models. Its nanomolar cellular activity and ATRX-aware glioma strategy help researchers connect receptor phosphorylation with functional cancer phenotypes.

• JNJ-10198409: PDGF Receptor Inhibitor

  2026-08-19

  JNJ-10198409 is a platelet-derived growth factor receptor inhibitor that targets the ATP-binding site of the PDGF-BB receptor tyrosine kinase. Its reported in vitro IC50 is 4.2 nM in human coronary artery smooth muscle cells, supporting use in PDGF-driven proliferation, angiogenesis, tumor-growth, and fibrotic disorder research.

• Rab26, SERT Trafficking, and Behavioral Deficits

  2026-08-19

  The reference study identifies Rab26 as a regulator of serotonin transporter trafficking and links its deficiency to altered synaptic physiology, depression- and anxiety-like behavior, and cognitive impairment in mice. Its combination of behavioral, electrophysiological, and trafficking analyses provides a mechanistic framework for studying how membrane transport controls serotonin signaling, while also suggesting biochemical workflows for analyzing transporter surface abundance and protein interactions.

• Atorvastatin Workflows for Metabolism and Vascular Studies

  2026-08-18

  Build reproducible Atorvastatin experiments across cholesterol metabolism research, vascular phenotyping, and emerging ferroptosis studies. This practical guide connects dose selection, orthogonal readouts, formulation control, and troubleshooting without overstating preclinical evidence.

• Dasatinib: A Causal Signaling Assay Framework

  2026-08-18

  Dasatinib (BMS-354825) can do more than suppress kinase activity: it can help researchers separate proximal Src–FAK signaling from downstream EMT and stemness phenotypes. This assay-focused guide connects product parameters with the SNAI1–PIK3R2/p-EphA2 findings in thymic epithelial tumors while clearly defining experimental limits.

• Toremifene vs Tamoxifen in Advanced Breast Cancer

  2026-08-17

  This Cochrane review evaluates whether toremifene offers clinically meaningful advantages over tamoxifen for advanced breast cancer. Its main contribution is a direct, outcome-by-outcome synthesis of randomized evidence, which found no convincing basis for claiming superiority in tumor response, disease control, survival, or selected adverse events.

• CA800-PR Targets Golgi Stress in HR+ Breast Cancer

  2026-08-17

  A 2026 Theranostics study describes CA800-PR, a hydrophilic heptamethine cyanine dye designed to combine tumor targeting, near-infrared imaging, and treatment in hormone receptor-positive breast cancer. The study links CA800-PR to Golgi fragmentation, selective progesterone receptor suppression, apoptosis, and recruitment of antitumor M1-type macrophages in cellular and xenograft models.

• Sulfaphenazole-Derived Sulfonamides for TB

  2026-08-16

  Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP 2C9 inhibition, a liability associated with drug–drug interaction risk. Compound 10d emerged as the most informative lead, combining a reported MIC of 5.69 μg/mL with CYP 2C9 IC50 greater than 10 μM and low cytotoxicity.

• Idoxuridine: Viral DNA Synthesis Inhibition

  2026-08-15

  Idoxuridine, also called 5-iodo-2'-deoxyuridine, is a nucleoside analog used to investigate viral DNA synthesis inhibition. Its research value comes from a defined DNA replication disruption mechanism, while solvent compatibility, storage, cytotoxicity controls, and assay-specific validation determine how results should be interpreted.

• AS1842856 Foxo1 Inhibitor Workflow Guide

  2026-08-15

  Use AS1842856 to separate Foxo1 activity from Foxo1 abundance in gluconeogenesis, autophagy, and pathway-rewiring experiments. This workflow connects hepatic metabolic assays with the PI3K-Akt-Foxo1 biology of mesenchymal stem cells while clearly distinguishing validated applications from exploratory use.

• Quizartinib (AC220): From FLT3 Biology to Translation

  2026-08-14

  Quizartinib (AC220) offers a focused way to interrogate FLT3 dependency, target engagement, and resistance in acute myeloid leukemia research. This thought-leadership guide connects molecular selectivity with assay design, xenograft strategy, biomarker interpretation, and the emerging FLT3–TAZ resistance biology described in blast phase CML.

• SCH772984: A Practical ERK1/2 Inhibitor Workflow

  2026-08-14

  SCH772984 enables selective, nanomolar interrogation of ERK1/2 signaling across BRAF, NRAS, and KRAS-driven tumor models. This workflow connects pathway pharmacology with clonogenic, ferroptosis, radiation, and xenograft readouts while separating validated evidence from hypothesis-generating applications in nasopharyngeal carcinoma.

• Cy5 amine (non-sulfonated): Practical Labeling Guide

  2026-08-13

  Cy5 amine (non-sulfonated), SKU A8143, provides a primary amino group for covalent attachment to activated biomolecules while producing red fluorescence near 662 nm. It is water-insoluble, so researchers should prepare it in DMSO or ethanol before transfer into a compatible aqueous labeling workflow; it is intended for research use only and not for diagnostic or medical applications.

449 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page